Columns The MS Wire - A Column by Ed Tobias MS News Notes: Sexual Dysfunction, Bladder Problems, AI, and More MS News Notes: Sexual Dysfunction, Bladder Problems, AI, and More Columnist Ed Tobias comments on the week's top MS news by Ed Tobias | December 5, 2022 Share this article: Share article via email Copy article link Welcome to āMS News Notes,ā where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Hereās a look at whatās been happening: A medication that may ease sexual problems for women with MS Sexual dysfunction is common among people with MS, affecting up to 80% of women and 90% of men. But an antidepressant pill that’s been around since 1985 may be able to help. As MS News Today‘s Lindsey Shapiro reports in “Antidepressant Bupropion Found to Ease Sexual Dysfunction in MS,” bupropion ā marketed as Wellbutrin and Zyban, among others ā may increase the levels of two brain molecules that involve sexual desire, arousal, and orgasm. Unfortunately, guys, this study only involved women. Some help for men with bladder frequency and urgency Most of us with MS have bladders that frequently “gotta go, gotta go.” Now, a small study reports that combining pelvic exercises with posterior tibial nerve stimulation (PTNS) could help. PTNS is a procedure that delivers electrical stimulation to the bladder through nerves in the leg. This stimulation may help to relax the muscles around the bladder, thereby easing the urgency and frequency that can be a bother. Marisa Wexler provides details in the MS News Today article “Electrical Stimulation Helps With Bladder Control in MS, Study Finds.” Unfortunately, ladies, this study only involved men. Recommended Reading November 17, 2022 Columns by Benjamin Hofmeister Striking a Balance Between Self-pity and Giving Yourself Grace Alcohol may interfere with Tecfidera treatments Here’s a word of caution for people with MS being treated with Tecfidera (dimethyl fumarate) and who like to drink alcohol. A recent study discussed in the MS News Today story “Alcohol May Interfere With Tecfidera Metabolism, Study Finds” warns that consuming alcohol around dosing time could limit Tecfidera’s effectiveness. Specifically, the results from lab work and mice showed that alcohol inhibited the creation of a small molecule that drives Tecfideraās therapeutic effects. It was completely absent in the blood and brain tissue of the test mice that had been given alcohol. Researchers recommended that “alcohol consumption be avoided in close temporal proximity to dosing with [dimethyl fumarate].” They didn’t indicate how much time people should wait between consuming alcohol and taking Tecfidera, nor how much alcohol might affect treatment. But considering that the medication is taken twice a week, it could be difficult to avoid close temporal proximity. The next step is to test alcohol’s effect on Tecfidera in humans, the researchers said. Researchers think this software could speed an MS diagnosis Software that can detect abnormalities just five minutes after scanning MRIs will soon be available in Europe, its creators say. The tool uses artificial intelligence to assess the images and pinpoint, quantify, and monitor abnormalities. Specifically, the software can provide quantified information about lesions and other forms of brain damage, as well as data on brain volume loss. It is currently being used to help doctors diagnose strokes. MS News Today‘s Mary Chapman has the details in her story “Pixyl, Brainomix Partner on MRI Software to Help in Diagnosis of MS.” Note:Ā Multiple Sclerosis News TodayĀ is strictly a news and information website about the disease. It does not provide medical advice,Ā diagnosis, orĀ treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those ofĀ Multiple Sclerosis News TodayĀ or its parent company, BioNews, and are intended to spark discussion about issues pertaining to multiple sclerosis. Print This Page About the Author Ed Tobias People say to write what you know and Ed Tobias knows about MS. He's lived with the illness since 1980, when he was 32 years old. Ed's a retired, award-winning broadcast journalist and his column combines his four decades of MS experiences with news and comments about the latest in the MS community. In addition to writing his column, Ed is one of the patient moderators on the MS News Today Facebook, Twitter, and Instagram sites. Heās also the author of āThe Multiple Sclerosis Toolbox: Hints and Tips for Living with M.S.ā Ed and his wife split their time between the Washington, D.C. suburbs and Floridaās Gulf Coast, trying to follow the sun. Tags MS News Comments Leave a comment Fill in the required fields to post. Your email address will not be published. Your Name Your Email Your Comment Post Comment
May 2, 2024 News by Marisa Wexler, MS Immigrants to Canada see MS risk rising with time in country: Study
April 30, 2024 News by Andrea Lobo, PhD Committee favors approval of under-the-skin Ocrevus in Europe